29 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our
10-Q
2024 Q1
EX-31.1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
of this Agreement:
“Cause” means any of the following with respect to Executive: (i) engaging in any acts of fraud, theft or embezzlement involving
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any
424B3
6cswv
16 Apr 24
Prospectus supplement
5:49pm
424B3
sizdexu57xrh2r338yw
16 Apr 24
Prospectus supplement
5:45pm
10-K
pdosm
16 Apr 24
Annual report
4:48pm
10-K
EX-31.1
x7wlb6
16 Apr 24
Annual report
4:48pm
10-K
EX-31.2
mpumsx9erqbmukqdskxn
16 Apr 24
Annual report
4:48pm
8-K
EX-3.2
eqflw4u4omn4m2sw
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
6ut7d d0aoj
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
bw0evfyihuebf
20 Feb 24
Prospectus supplement with pricing info
5:28pm